Delivery Order SPE2DB22D3004-SPE2DB25FSC16
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $11,725.57 and an ultimate completion date of August 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) pharmaceutical product, with a contract ceiling value of $1,253.36. The award, issued on July 31, 2025, carries a firm fixed price structure with an ultimate completion date of August 1, 2025. This non-competitive, non-set-aside delivery order represents part of AmerisourceBergen's ongoing support of federal medical supply chains, with performance fulfilled from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $29,042.05. This firm fixed-price delivery order, which is set to be completed by August 19, 2025, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $1,758.99. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a contract ceiling value of $5,243.63. This firm fixed-price delivery order, which has an ultimate completion date of July 25, 2025, will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award utilized no set-aside designation and was competitively awarded through...
- The Defense Logistics Agency awarded a $11,665.96 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. Performance will be conducted at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This award falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $42,114.61. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of August 4, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a ceiling value of $1,112.89. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's capability to compete in open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, valued at $31,332.93. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The performance...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSC16Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $1,090.14. The award, issued on August 21, 2025, represents a competitively awarded, firm fixed-price delivery order with no set-aside designation and an ultimate completion date of August 22, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The IDC enables AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. Ozempic, a diabetes management medication, represents one of the therapeutic domains within the company's federal pharmaceutical portfolio serving the Defense Health Agency and other government healthcare systems. The award demonstrates AmerisourceBergen's ongoing capability to fulfill federal medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/21/25 |